Retroviral-vector-mediated gene therapy to mucopolysaccharidosis i mice improves sensorimotor impairments and other behavioral deficits

Guilherme Baldo, David F. Wozniak, Kevin K. Ohlemiller, Yanming Zhang, Roberto Giugliani, Katherine P. Ponder

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Mucopolysaccharidosis I (MPS I) is a lysosomal storage disease due to α-L-iduronidase (IDUA) deficiency that results in the accumulation of glycosaminoglycans (GAG). Systemic gene therapy to MPS I mice can reduce lysosomal storage in the brain, but few data are available regarding the effect upon behavioral function. We investigated the effect of gene therapy with a long-terminal-repeat (LTR)-intact retroviral vector or a self-inactivating (SIN) vector on behavioral function in MPS I mice. The LTR vector was injected intravenously to 6-week-old MPS I mice, and the SIN vector was given to neonatal or 6-week-old mice. Adult-LTR, neonatal-SIN, and adult-SIN-treated mice achieved serum IDUA activity of 235 ± 20 (84-fold normal), 127 ± 10, and 71 ± 7 U/ml, respectively. All groups had reduction in histochemical evidence of lysosomal storage in the brain, with the adult-LTR group showing the best response, while adult-LTR mice had reductions in lysosomal storage in the cristae of the vestibular system. Behavioral evaluation was performed at 8 months. Untreated MPS I mice had a markedly reduced ability to hold onto an inverted screen or climb down a pole. LTR-vector-treated mice had marked improvements on both of these tests, whereas neonatal-SIN mice showed improvement in the pole test. We conclude that both vectors can reduce brain disease in MPS I mice, with the LTR vector achieving higher serum IDUA levels and better correction. Vestibular abnormalities may contribute to mobility problems in patients with MPS I, and gene therapy may reduce symptoms.

Original languageEnglish
Pages (from-to)499-512
Number of pages14
JournalJournal of Inherited Metabolic Disease
Issue number3
StatePublished - May 2013


Dive into the research topics of 'Retroviral-vector-mediated gene therapy to mucopolysaccharidosis i mice improves sensorimotor impairments and other behavioral deficits'. Together they form a unique fingerprint.

Cite this